Related references
Note: Only part of the references are listed.New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland
Pirkko Kriikku et al.
FORENSIC SCIENCE INTERNATIONAL (2011)
Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS
Markus R. Meyer et al.
JOURNAL OF MASS SPECTROMETRY (2010)
Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry
Sabina Strano-Rossi et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2010)
Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure
Folker Westphal et al.
FORENSIC SCIENCE INTERNATIONAL (2009)
1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors
PC Meltzer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types - A synopsis
HH Maurer et al.
THERAPEUTIC DRUG MONITORING (2004)
Pharmacogenetics and pharmacogenomics
JS Leeder
PEDIATRIC CLINICS OF NORTH AMERICA (2001)
Share Paper
